User:Mr. Ibrahem/Procainamide
Clinical data | |
---|---|
Pronunciation | /proʊˈkeɪnəmaɪd/ |
Trade names | Pronestyl, Procan, Procanbid, others |
AHFS/Drugs.com | Monograph |
Routes of administration | IV, IM, by mouth[1] |
Drug class | Antiarrhythmic[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 85% (by mouth) |
Protein binding | 15 to 20% |
Metabolism | Liver (CYP2D6-mediated) |
Onset of action | Within 30 min[1] |
Elimination half-life | ~2.5 to 4.5 hours |
Excretion | Kidney |
Identifiers | |
| |
Chemical and physical data | |
Formula | C13H21N3O |
Molar mass | 235.331 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Procainamide is a medication of the antiarrhythmic type.[1] It is used to treat heart arrhythmias including ventricular tachycardia and atrial fibrillation when people are otherwise stable.[1] Other uses have included malignant hyperthermia.[1] It is generally given by injection into a vein or muscle.[1] Onset is generally within 30 minutes.[1]
Common side effects include low blood pressure, itchiness, fever, and angioedema.[1] Other side effects effects may include bone marrow suppression and arrhythmias.[1] It is believed to be safe in the later part of pregnancy.[2] Use during breastfeeding is not recommended.[2] It is classified as a Ia Vaughan Williams antiarrhythmic.[1] How it works is not entirely clear by may involve sodium channel blocking in heart muscle cells.[1]
Procainamide was approved for medical use in the United States in 1950.[1] It is available as a generic medication.[3] In the United Kingdom it is only available by special order.[4]
References[edit]
- ^ a b c d e f g h i j k l m n o "Procainamide Monograph for Professionals". Drugs.com. Archived from the original on 20 January 2021. Retrieved 25 December 2020.
- ^ a b "Procainamide Use During Pregnancy". Drugs.com. Archived from the original on 2 December 2020. Retrieved 25 December 2020.
- ^ Nitzki-George, Diane (2003). Generic Alternatives to Prescription Drugs. Basic Health Publications, Inc. p. 882. ISBN 978-1-59120-098-7. Archived from the original on 2021-08-29. Retrieved 2020-12-25.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 108. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link)